93202-41-6Relevant articles and documents
KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
-
Paragraph 0141, (2019/06/05)
The present invention is directed to kinase inhibitor compounds having the following structure: or a stereoisomer, pharmaceuticallyacceptable salt, oxide, or solvate thereof, where R1, R2, X, n, R3, Y, Z, R4, R
COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS
-
Paragraph 0064; 0065, (2018/04/20)
Compounds and compositions are presented that inhibit K-ras, and especially mutant K-ras. Certain compounds preferentially or even selectively inhibit specific forms of mutant K-Ras, and particularly the G12D mutant form.
MIF INHIBITORS
-
Page/Page column 56, (2008/06/13)
The present invention relates to the use of specific benzimidazolone analogues and derivatives to inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF), and diseases or conditions wherein MIF cytokine or biological activity is implicated. Novel benzimidazole analogues and derivatives are also provided.